![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-92b89aa2ec304e03225793a05d96e64659ac6b6f92c40b7b2d5ce58a2861952d.jpg)
Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.